STAR Study Investigating Performance and Safety of the Medical Device SiPore15™

Overweight Clinical Trial

Official title:

Open-label, Single-arm, Multicenter Study Investigating Performance and Safety of SiPore15™ in Obese and Overweight Subjects With Prediabetes or Newly Diagnosed Type 2 Diabetes

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03823027
• Other study ID #: STAR01
• Status: Completed
• Phase: N/A
• Start date: January 28, 2019
• Est. completion date: October 2, 2019

Study information

• Verified date: November 2019
• Source: Sigrid Therapeutics AB
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary objective of STAR01 is to evaluate the performance and safety of the medical device (class IIb) SiPore15™ after a 12-week long treatment in the target population of obese and overweight subjects with prediabetes or newly diagnosed type 2 diabetes. The expected performance and safety of the device is based on the safety and efficacy results seen in an earlier First-in-Man (FIM) study. The safety and tolerability of SiPore15™ is based on the well-established and extensive use of food grade silicon dioxide and favorable data from the FIM study. Data on side-effects will be collected for verification of device safety. The study duration is 24 weeks in total, 12 weeks from baseline on investigational medicinal device (IMD) treatment, with additional 12 weeks off treatment. The study population is planned for forty (40) subjects to be enrolled, male and females, age >18 years and fulfilling all inclusion criteria but none of the exclusion criteria.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 43
• Est. completion date: October 2, 2019
• Est. primary completion date: October 2, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 105 Years

Eligibility

Inclusion Criteria:

1. Signed informed consent form.

2. Male or female aged =18 years on the day of screening.

3. Female subjects of childbearing potential must be on non-oral contraceptives, postmenopausal or sterile.

4. Prediabetes or newly diagnosed T2D (not on blood sugar lowering drugs) defined as HbA1c levels: =42 to =57 mmol/mol (=6.0 to =7.5%-according to DCCT).

5. Body mass index (BMI) >25 kg/m2 and > or = 40 kg/m2.

6. Stable weight for 3 months (+/-5 kg).

7. No extreme changes in diet for the last 6 months such as anorexia, bulimia, etc.

8. Subject must be able and willing to attend all scheduled visits and comply with all study procedures with no planned holiday longer than 2 weeks during the 12 weeks of treatment.

Exclusion Criteria:

1. Diagnosed with type1 diabetes/Latent Autoimmune Diabetes in Adult (LADA) or secondary diabetes, as part of medical history or confirmed by laboratory test.

2. Previous or current Metformin treatment or other glucose reducing drug therapy within 3 months before screening visit.

3. Previous or current statin treatment or other blood lipid (LDL) reducing drug therapy, within 12 months before screening visit.

4. Previous or current medication known to cause weight loss or weight gain, such as systemic corticosteroids, thyroid hormones or Estrogen, within 1 month before screening visit.

5. Subjects who stopped smoking within 6 months before screening visit.

6. Diagnosed with chronic somatic diseases, except for obesity and treatment naive T2D, that in the opinion of the investigator may therefore affect metabolic and /or intestinal function (e.g. inflammatory bowel disease, intestinal dysfunction, pancreatic dysfunction, other causes of malabsorption, recent (past 6 months) neoplastic disease.

7. Any history of myocardial infarction or stroke within the 6 months before screening visit.

8. Anemia, donated blood or other major blood loss within 3 months from screening visit that in the opinion of the clinician may interfere with the study.

9. Pregnancy or breast feeding.

10. Allergies to silicon dioxide.

11. A diagnosed state that requires use of vitamin and/or mineral supplements during the study.

12. Previous major gastric surgery that may affect the study outcome, such as bariatric surgery.

13. Ongoing or unstable kidney condition with moderate to great reduction in glomerular filtration rate < 90 ml/min (GFR) that may affect metabolic parameters during the trial.

14. Ongoing or unstable liver condition that may cause changes in liver enzymes exceeding 2x upper normal levels.

15. Psychiatric or cognitive disorder and/or behavioral problems which in the opinion of the clinician may interfere with the study.

16. History of or ongoing alcohol or drug addiction.

17. Participation in any study involving an investigational drug or medical device within the past 30 days before the screening visit.

18. Belongs to a vulnerable population or has any condition such that his/her ability to provide informed consent, comply with the follow-up requirements, or provide self- assessments is compromised (e.g. homeless, developmentally disabled and prisoner).

19. Is a relative of the Investigator or an employee at the clinical study site.

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus, Type 2
• Glucose Intolerance
• Obese
• Overweight
• Pre Diabetes
• PreDiabetes
• Prediabetic State
• Type2 Diabetes
• Type2 Diabetes Mellitus

Intervention

Device:
• SiPore15™
SiPore15™ is a taste- and odourless white powder, consisting of precisely engineered micrometre sized synthetic amorphous silicon dioxide. The device is made of pure silicon dioxide, SiO2, which has the CAS Number: 112926-00-8 and EC List number: 601-214-2.

Locations

Country	Name	City	State
Finland	Pihlajalinna Ite, Satucon OY	Kuopio
Sweden	Clinical Trial Consultants	Uppsala	Uppland

Sponsors (1)

Lead Sponsor	Collaborator
Sigrid Therapeutics AB

Countries where clinical trial is conducted

Finland,  Sweden, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Exploratory Endpoint on Medical Device Usability	To assess Medical Device Usability by collecting data: a. Collect information on Ease of use (Easy, neither/nor, difficult) at visit week 2, 6 and end-of -treatment.	From week 1 to week 12
Other	Explorative Endpoint on changes in Cholesterol	To measure change in total Cholesterol levels from baseline to week 6 and end-of-treatment.	From week 1 to week 12
Other	Explorative Endpoint on changes in microbiome diversity (species not defined)	To explore changes in microbiome by feces sampling for research at baseline and at week 24.	From week 1 to week 24
Primary	Performance measured as changes in HbA1c	To measure change in long-term blood glucose levels, HbA1c, from baseline (week 1) to end- -of-treatment (week 12).	From week 1 to week 12
Primary	Tolerability measured as evaluation of Adverse Events	To assess safety and tolerability by evaluating the frequency and incidence of both adverse events (AEs) and device related adverse events (ADEs) during the study treatment and follow-up, from baseline (week 1) until week 14.	From week 1 to week 14
Secondary	Performance measured as changes in LDL-C	To measure change in LDL-C blood levels from baseline (week 1) to week 6 and end-of- treatment (week 12).	From week 1 to week 12
Secondary	Performance measured as changes in body fat %	To measure change in body fat levels (bio electric impedance, BIA) from baseline (week 1) to week 6 and end-of-treatment (week 12).	From week 1 to week 12

External Links

•   Information about the site and study in Kuopio, Finland
•   Information about the site and study in Uppsala, Sweden